Alpha-7 Nicotinic Receptor Modulators for Adolescent Alcohol Neuroadaptation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for addressing the harmful neuroadaptations caused by adolescent alcohol consumption, which can lead to increased risks of alcohol use disorders and other addictions in adulthood, as they fail to effectively target the unique vulnerabilities of the adolescent brain.
Innovation Solution
Administration of therapeutically effective doses of negative modulators of the alpha-7 nicotinic receptor, such as norketamine, dehydronorketamine, and SB-27701-A, to adolescents to mitigate the effects of binge-like alcohol consumption, potentially reducing the likelihood of developing alcohol use disorders and related conditions in adulthood.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to address alcohol use disorder, then treatment availability is improved, but effectiveness in addressing harmful neuroadaptations from adolescent alcohol consumption is insufficient
Solution Approach 1:
The patent changes the pharmacological parameter by introducing negative modulators of alpha-7 nicotinic receptors, which have different mechanisms of action compared to current treatments. This parameter change enables the treatment to specifically target neuroadaptations caused by adolescent alcohol consumption, improving treatment effectiveness for this specific population.
Solution Approach 2:
The alpha-7 nicotinic receptor negative modulators act as intermediary substances that mediate between the harmful effects of adolescent alcohol consumption and the treatment outcome. These modulators specifically interfere with the neuroadaptations caused by alcohol, providing a targeted treatment mechanism that current therapies lack.
2Manufacturing precision
If treatments are developed specifically for adolescent brain vulnerabilities, then treatment precision is improved, but treatment complexity increases
Solution Approach 1:
The patent applies local quality by developing treatments specifically tailored to the adolescent brain's unique vulnerabilities and neuroadaptations. The negative modulators of alpha-7 nicotinic receptors are designed to specifically address the neural changes occurring during adolescence, providing precise treatment for this developmental stage without requiring complex multi-component therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of alpha-7 nicotinic receptor negative modulators has shown potential in reducing the harmful effects of adolescent alcohol consumption on the developing brain, thereby decreasing the risk of adult alcohol use disorders and related conditions, while avoiding adverse cognitive impacts.
Implementation Method 1
administering to a subject at least one therapeutically effective dose of at least one agent comprising at least one negative modulator of alpha-7 nicotinic receptor
Data Source
AI summary
Various aspects and embodiments disclosed herein relate generally to treating an alcohol use disorder or neuroadaptations. Embodiments include compositions and methods for modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with alcohol use disorders, or a related clinical condition thereof. Other embodiments include methods and compositions for reducing the effects of adolescent alcohol drinking.